ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH METRONOMIC CHEMOTHERAPY (MPEBEV REGIMEN) IN METASTATIC NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Correale, Pierpaolo
Botta, Cirino
Martellucci, Ignazio
Licchetta, Antonella
Migali, Cristina
Bestoso, Elena
Apollinari, Serena
Guglielmo, Annamaria
Rossi, Marcello
Addeo, Raffaele [2 ]
Luzzi, Luca [1 ]
Gotti, Giuseppe
Tagliaferri, Pierosandro [3 ]
机构：
[1] S Maria Alle Scotte Hosp, Thorac Surg Unit, Siena, Italy
[2] S Giovanni Di Dio Hosp, San Giovanni Rotondo, Italy
[3] Magna Graecia, Catanzaro, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; bevacizumab; metronomic-chemotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1237 / S1237
页数：1
相关论文
共 50 条
  • [31] ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH PEMETREXED AS MAINTENANCE THERAPY FOR NON-SMALL CELL LUNG CANCER IN A XENOGRAFT MODEL: COMPARISON WITH PEMETREXED MONOTHERAPY AND ANALYSIS OF THE COMBINATION MECHANISM
    Ishikura, Nobuyuki
    Yamamoto, Kaname
    Iwai, Toshiki
    Yorozu, Keigo
    Kurasawa, Mitsue
    Harada, Naoki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S769 - S769
  • [32] A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
    Yokoi, Takashi
    Tamaki, Takeshi
    Shimizu, Toshiki
    Nomura, Shosaku
    LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 15 - 20
  • [33] EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer
    De Marinis, Filippo
    Bidoli, Paolo
    Luciani, Andrea
    Amoroso, Domenico
    Tonini, Giuseppe
    Bertolini, Alessandro
    Brandes, Alba A.
    Migliorino, Maria Rita
    Favaretto, Adolfo
    Gridelli, Cesare
    ANTICANCER RESEARCH, 2017, 37 (05) : 2457 - 2464
  • [34] COST-UTILITY OF BEVACIZUMAB WITH PC REGIMEN IN NON-SMALL CELL LUNG CANCER TREATMENT
    Nguyen, T. T. T.
    Tran, T. T. H.
    VALUE IN HEALTH, 2014, 17 (07) : A725 - A725
  • [35] Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC)
    William, W. N., Jr.
    Kies, M. S.
    Fossella, F. V.
    Gladish, G.
    Heymach, J. V.
    Glisson, B. S.
    Tse, W. H.
    Liu, D.
    Herbst, R. S.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Chemotherapy in non-small cell lung cancer
    Sweeney, CJ
    Sandler, AB
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (02) : 157 - 186
  • [37] Chemotherapy in Non-Small Cell Lung Cancer
    Christopher J. Sweeney
    Alan B. Sandler
    Investigational New Drugs, 2000, 18 : 157 - 186
  • [38] Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer
    Chino, Haruka
    Amano, Yosuke
    Yamauchi, Yasuhiro
    Matsuda, Jun
    Takeda, Norihiko
    Tanaka, Goh
    Takai, Daiya
    Nagase, Takahide
    JOURNAL OF THORACIC DISEASE, 2016, 8 (09) : 2646 - 2650
  • [39] Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS
    Polikoff, J.
    Hainsworth, J. D.
    Fehrenbacher, L.
    Royer-Joo, S.
    Mu, Y.
    Strickland, D. K.
    Miller, V. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer
    Duan, Jianchun
    Yang, Zhenhua
    Liu, Dingyuan
    Zhang, Zhen
    Shi, Yunfei
    JOURNAL OF BUON, 2018, 23 (05): : 1402 - 1406
12345